Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...
Morning Overview on MSN
The FDA cleared a three-drug maintenance combination for HER2-positive breast cancer built around tucatinib
Tucatinib, trastuzumab and pertuzumab became an approved maintenance regimen on Oct. 7, 2026, when the Food and Drug ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
Eli Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA in its first frontline indication for chronic ...
DeLLphi-305 randomized 563 nonprogressing ES-SCLC patients post induction durvalumab plus platinum/etoposide to durvalumab maintenance with or without tarlatamab, with overall survival as the primary ...
BeOne Medicines, a global oncology company, today announced the successful completion of negotiations with the pan-Canadian ...
Christa Pike, the woman who survived Tennessee's attempt to execute her by lethal injection, has been moved back to prison.
Zacks Investment Research on MSN
FDA expands Eli Lilly's blood cancer drug label in first-line setting
Eli Lilly LLY announced that the FDA has expanded the label of its oral cancer drug Jaypirca (pirtobrutinib) to include a new ...
Christa Pike is the first known prisoner to survive a lethal injection. Christa Pike, a Tennessee death row inmate who ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
NEJM reviews major breast cancer treatment advances since 2020, from ADCs and CDK4/6 inhibitors to immunotherapy, oral SERDs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results